Viatris
-
Viatris bags Global Minimized Risk of Antimicrobial Resistance Certification
Aurangabad in Maharashtra is the country’s first pharmaceutical facility, and the first in Viatris’ network, to meet the new British…
Read More » -
Viatris announces US FDA tentative approval of paediatric formulation for children living with HIV
Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence to HIV treatment for…
Read More » -
Biocon Biologics completes acquisition of Viatris’ global biosimilars biz
Viatris to provide commercial and other services for up to 2 years to ensure a seamless transition and continued service…
Read More » -
Biocon Biologics, Viatris launch Abevmy in Canada
The two formats of Abevmy are available in 100 mg/4 mL single-use vial and 400 mg/16 mL single-use vial Biocon…
Read More » -
Biocon Biologics to acquire Viatris’ biosimilars assets
The acquisition will be for up to $3.335 billion in stock and cash Biocon Biologics, a subsidiary of Biocon has…
Read More » -
Biocon Biologics, Viatris launch Interchangeable SEMGLEE and Insulin Glargine injection
The injections will help control high blood sugar in adult and paediatric patients with type 1 diabetes and adults with…
Read More » -
Biocon Biologics, Viatris receive US FDA nod for Semglee
Semglee is used in the treatment of diabetes Biocon Biologics and Viatris announced that the US Food and Drug Administration…
Read More » -
Biocon Biologics promotes Shreehas Tambe as Deputy CEO
In another development, Biocon Biologics, Viatris get CHMP Nod for Abevmy Biocon Biologics announced that Shreehas Tambe has been promoted…
Read More »